Literature DB >> 3048475

Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.

D Przepiorka1, E D Thomas.   

Abstract

The cytogenetic data for 126 patients with Ph-positive chronic myelogenous leukemia (CML) in accelerated phase or blast crisis were analysed for clonal chromosomal abnormalities in addition to the standard Ph prior to allogeneic or syngeneic bone marrow transplantation (BMT). Additional clonal abnormalities were found in 84%, and 14% had a variant Ph (VPh). In decreasing order of frequency, the most common clonal abnormalities were a second Ph, +8, i(17q), -Y and +19. A second Ph, VPh or +8 occurred more frequently in patients who relapsed following BMT than in those who survived disease-free for at least 1 1/2 years. The presence of an i(17q) alone did not correlate with relapse. The patients with a second Ph, VPh or +8 had a median time to relapse of 19 months, and the risk of relapse at 3 years was 73%. Those with other or no additional clonal abnormalities had not reached a median time to relapse and had a 3-year risk of relapse of 31% (p = 0.002). This analysis suggests that specific cytogenetic abnormalities may be useful indicators of resistance to therapy for CML and should be included in proportional hazard models to predict outcome after BMT.

Entities:  

Mesh:

Year:  1988        PMID: 3048475

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.

Authors:  Dushyant Verma; Hagop Kantarjian; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

Review 2.  Management of Chronic Myeloid Leukemia in Advanced Phase.

Authors:  Massimiliano Bonifacio; Fabio Stagno; Luigi Scaffidi; Mauro Krampera; Francesco Di Raimondo
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.